Risk factors for and impact of carbapenem-resistant Acinetobacter baumannii colonization and infection: matched case–control study

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 34, Issue 10, 2015, Pages 2063-2068

  Henig, O ^a,b   Weber, G ^a,d   Hoshen, M B ^b   Paul, M ^c   German, L ^b   Neuberger, A ^c,d   Gluzman, I ^b   Berlin, A ^b   Shapira, C ^a,d   Balicer, R D ^b,e  

^a CARMEL MEDICAL CENTER   (Israel)

^b CLALIT HEALTH SERVICES   (Israel)

^c Division of Infectious Diseases   (Israel)

^d Lady Davis Carmel Medical Center ^*  (Israel)

^e BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; IMMUNOSUPPRESSIVE AGENT; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; AGE; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIUM ISOLATION; CARBAPENEM RESISTANT ACINETOBACTER BAUMANNII; CHARLSON COMORBIDITY INDEX; CHRONIC DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; FEMALE; HEALTHCARE ASSOCIATED INFECTION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MORTALITY; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; SOCIAL STATUS; ACINETOBACTER INFECTIONS; ADULT; CASE CONTROL STUDY; COMPARATIVE STUDY; CROSS INFECTION; DRUG EFFECTS; ISRAEL; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; MULTIDRUG RESISTANCE; ODDS RATIO; RETROSPECTIVE STUDY; RISK FACTOR; SOCIOECONOMICS; VERY ELDERLY; YOUNG ADULT;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CARBAPENEMS; CASE-CONTROL STUDIES; COHORT STUDIES; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; ISRAEL; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; ODDS RATIO; RETROSPECTIVE STUDIES; RISK FACTORS; SOCIOECONOMIC FACTORS; YOUNG ADULT;

EID: 84941416804     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-015-2452-4     Document Type: Article

References (25)

1. Villegas MV, Hartstein AI (2003) Acinetobacter outbreaks, 1977–2000. Infect Control Hosp Epidemiol 24(4):284–295
2. Dijkshoorn L, Nemec A, Seifert H (2007) An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol 5(12):939–951
3. Ruiz J, Núñez ML, Pérez J, Simarro E, Martínez-Campos L, Gómez J (1999) Evolution of resistance among clinical isolates of Acinetobacter over a 6-year period. Eur J Clin Microbiol Infect Dis 18(4):292–295
4. Agodi A, Voulgari E, Barchitta M, Quattrocchi A, Bellocchi P, Poulou A et al (2014) Spread of a carbapenem- and colistin-resistant Acinetobacter baumannii ST2 clonal strain causing outbreaks in two Sicilian hospitals. J Hosp Infect 86(4):260–266
5. Falagas ME, Kopterides P (2006) Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J Hosp Infect 64(1):7–15
6. Wadl M, Heckenbach K, Noll I, Ziesing S, Pfister W, Beer J et al (2010) Increasing occurrence of multidrug-resistance in Acinetobacter baumannii isolates from four German University Hospitals, 2002–2006. Infection 38(1):47–51
7. Abbo A, Carmeli Y, Navon-Venezia S, Siegman-Igra Y, Schwaber MJ (2007) Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes. Eur J Clin Microbiol Infect Dis 26(11):793–800
8. Sunenshine RH, Wright MO, Maragakis LL, Harris AD, Song X, Hebden J et al (2007) Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 13(1):97–103
9. del Mar Tomas M, Cartelle M, Pertega S, Beceiro A, Llinares P, Canle D et al (2005) Hospital outbreak caused by a carbapenem-resistant strain of Acinetobacter baumannii: patient prognosis and risk-factors for colonisation and infection. Clin Microbiol Infect 11(7):540–546
10. Lee SO, Kim NJ, Choi SH, Hyong Kim T, Chung JW, Woo JH et al (2004) Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a case–control study. Antimicrob Agents Chemother 48(1):224–228
11. Playford EG, Craig JC, Iredell JR (2007) Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: risk factors for acquisition, infection and their consequences. J Hosp Infect 65(3):204–211
12. Corbella X, Montero A, Pujol M, Domínguez MA, Ayats J, Argerich MJ et al (2000) Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J Clin Microbiol 38(11):4086–4095
13. Tacconelli E, Cataldo MA, De Pascale G, Manno D, Spanu T, Cambieri A et al (2008) Prediction models to identify hospitalized patients at risk of being colonized or infected with multidrug-resistant Acinetobacter baumannii calcoaceticus complex. J Antimicrob Chemother 62(5):1130–1137
14. Routsi C, Pratikaki M, Platsouka E, Sotiropoulou C, Nanas S, Markaki V et al (2010) Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes. Infection 38(3):173–180
15. Levin AS, Mendes CM, Sinto SI, Sader HS, Scarpitta CR, Rodrigues E et al (1996) An outbreak of multiresistant Acinetobacter baumanii in a university hospital in São Paulo, Brazil. Infect Control Hosp Epidemiol 17(6):366–368
16. Falagas ME, Bliziotis IA, Siempos II (2006) Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case–control studies. Crit Care 10(2):R48
17. Horan TC, Andrus M, Dudeck MA (2008) CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 36(5):309–332
18. Villar M, Cano ME, Gato E, Garnacho-Montero J, Miguel Cisneros J, Ruíz de Alegría C et al (2014) Epidemiologic and clinical impact of Acinetobacter baumannii colonization and infection: a reappraisal. Medicine 93(5):202–210
19. Bonelli RR, Moreira BM, Picão RC (2014) Antimicrobial resistance among Enterobacteriaceae in South America: history, current dissemination status and associated socioeconomic factors. Drug Resist Updat 17(1–2):24–36
20. Kristiansson C, Grape M, Gotuzzo E, Samalvides F, Chauca J, Larsson M et al (2009) Socioeconomic factors and antibiotic use in relation to antimicrobial resistance in the Amazonian area of Peru. Scand J Infect Dis 41(4):303–312
21. Kirby A, Herbert A (2013) Correlations between income inequality and antimicrobial resistance. PLoS One 8(8):e73115
22. Mackall C, Fry T, Gress R, Peggs K, Storek J, Toubert A (2009) Background to hematopoietic cell transplantation, including post transplant immune recovery. Bone Marrow Transplant 44(8):457–462
23. Lautenbach E, Synnestvedt M, Weiner MG, Bilker WB, Vo L, Schein J et al (2009) Epidemiology and impact of imipenem resistance in Acinetobacter baumannii. Infect Control Hosp Epidemiol 30(12):1186–1192
24. Harris AD, Karchmer TB, Carmeli Y, Samore MH (2001) Methodological principles of case–control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin Infect Dis 32(7):1055–1061
25. Harris AD, Samore MH, Lipsitch M, Kaye KS, Perencevich E, Carmeli Y (2002) Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli. Clin Infect Dis 34(12):1558–1563